Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Contraception Age: Adult |
Dose: Tablet – one white tablet Frequency: once daily Duration: 21 consecutive days Note: Recommended to be taken at the same time each day |
|
Indication: Contraception Age: Adult |
Dose: Tablet – one orange inert tablet Frequency: once daily Duration: 7 consecutive days Note: Following the 21 days of active tablets; recommended to be taken at the same time each day |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Contraception Age: Postmenarchal females |
Dose: Tablet – 1 tablet Frequency: once daily Note: by mouth (oral) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment |
Dose: Not specified Note: Use caution; monitor blood pressure |
Administration
- Take at same time daily
- Follow 28-day cycle
Side Effect
- Menstrual irregularities
- headache
- dizziness
- breast discomfort
- gynaecomastia
- depression
- disturbance of appetite
- weight changes
- fluid retention
- oedema
- changes in libido
- hair loss or hirsutism
- GI disturbances (nausea and vomiting)
- genitourinary changes
- haematologic disorders
- endocrine and metabolic disorders
- cholestatic jaundice
- local skin reactions
- chorea
- contact lens intolerance
- steeping of corneal curvature
- pulmonary thromboembolism
- carbohydrate and/or glucose intolerance
- depression
- chloasma
- BP increase
- liver impairment
- reduced menstrual loss
- 'spotting' in early cycles
- absence of withdrawal bleeding
- rarely photosensitivity
- increased risk in breast cancer
- elevation of plasma bound iodine
- cortisol and thyroid binding
- erythrocyte sedimentation may be accelerated
- increases in plasma copper
- iron and alkaline phosphatase
- may affect serum triglyceride and lipoprotein levels
- retinal vascular thrombosis
- Hepatic tumours
- increased risk of thromboembolism
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 inducers (e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin, ritonavir)
|
May decrease levels/effects
|
|
Ampicillin, tetracycline, other antibiotics
|
May reduce efficacy
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe arterial disease
|
Risk of blood clots
|
|
Liver adenoma
|
Risk of tumor growth
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.